Atherosclerosis and Lipoproteins |
0), Is Associated With Low HDL Cholesterol Levels and Decreased Cholesterol Efflux From Cells
From the Department of Internal Medicine, School of Medicine, Fukuoka University, Fukuoka (H. Han, J.S., A.M., W.H., T.K., K.A.); the Department of Internal Medicine, Miyazaki Prefectural Nichinan Hospital, Nichinan (M.A., T.T.); and the Department of Biochemistry, Kumamoto University, School of Medicine, Kumamoto (H. Hakamata, S.H.), Japan.
Correspondence to Jun Sasaki, MD, Department of Internal Medicine, School of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. E-mail mm03455{at}msat.fukuoka-u.ac.jp
AbstractA novel variant of
apolipoprotein (apo) A-I associated with low high density lipoprotein
(HDL) cholesterolemia has been identified in a Japanese
family during screening for apoA-I variants by isoelectric focusing
(IEF) gel analysis. ApoA-I (Glu235
0) Nichinan was caused by
a 3-bp deletion of nucleotides 1998 through 2000 in exon 4
of the apoA-I gene. Four subjects in the family were heterozygous
carriers for this mutation; the mean plasma concentrations of apoA-I
and HDL cholesterol of affected family members were 30%
and 32% lower, respectively, than those of unaffected family members.
There were no differences in the levels of very low density lipoprotein
and low density lipoprotein cholesterol,
triglycerides, and other apolipoproteins between the
carriers and the noncarrier family members. In the proband, plasma
lecithin:cholesterol acyltransferase activity was normal.
Functional consequences of the mutation were examined by expressing the
mutated and wild-type proapoA-I cDNAs in Escherichia
coli. Cholesterol efflux to recombinant
proapoA-I Nichinan from mouse peritoneal macrophages loaded
with [3H]cholesterol-labeled
acetylated low density lipoprotein was decreased by 54% when
compared that of normal recombinant proapoA-I. In vivo turnover studies
in normal rabbits demonstrated that the recombinant proapoA-I Nichinan
was rapidly cleared (22% faster) compared with normal
recombinant proapoA-I. We conclude that apoA-I (Glu235
0) Nichinan
induced a critical structural change in the carboxyl-terminal domain of
apoA-I for cellular cholesterol efflux and increased the
catabolism of apoA-I, resulting in low HDL cholesterol levels.
Key Words: HDL cholesterol apoA-I variant cholesterol efflux kinetics
This article has been cited by other articles:
![]() |
A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sviridov, A. Hoang, W. Huang, and J. Sasaki Structure-function studies of apoA-I variants: site-directed mutagenesis and natural mutations J. Lipid Res., August 1, 2002; 43(8): 1283 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Frank and Y. L. Marcel Apolipoprotein A-I: structure;-function relationships J. Lipid Res., June 1, 2000; 41(6): 853 - 872. [Abstract] [Full Text] |
||||
![]() |
W. Huang, J. Sasaki, A. Matsunaga, H. Han, W. Li, T. Koga, M. Kugi, S. Ando, and K. Arakawa A Single Amino Acid Deletion in the Carboxy Terminal of Apolipoprotein A-I Impairs Lipid Binding and Cellular Interaction Arterioscler. Thromb. Vasc. Biol., January 1, 2000; 20(1): 210 - 216. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |